Press Releases
Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of...
Bristol-Myers Squibb Company (NYSE:BMY) today announced results from CheckMate -017, a Phase III, open-label, randomized study evaluating Opdivo (n=135) versus docetaxel (n=137) in previously treated...
Press Releases
Phase III CheckMate -067 Trial Demonstrates Superior Progression-Free Survival...
Bristol-Myers Squibb Company (NYSE:BMY) today announced positive results of a Phase III trial (CheckMate -067) evaluating the Opdivo (nivolumab)+Yervoy (ipilimumab) regimen or Opdivo monotherapy vs....
Press Releases
Lilly to Participate in Goldman Sachs Global Healthcare Conference
Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 36th Annual Global Healthcare Conference on Tuesday, June 9, 2015. Jeffrey Simmons, senior vice...
Press Releases
Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical...
Eli Lilly and Company (NYSE: LLY) and AstraZeneca (NYSE: AZN) today announced that they have entered into a clinical trial collaboration to evaluate the safety...
Press Releases
Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibb’s PD-1...
Bristol-Myers Squibb Company (NYSE:BMY) today announced results from an interim analysis of CA209-040, a Phase I/II dose-ranging trial evaluating the safety and anti-tumor activity of...
Press Releases
Opdivo (nivolumab) First PD-1 Inhibitor to Demonstrate Superior Overall...
Bristol-Myers Squibb Company (NYSE:BMY) today announced that Opdivo (nivolumab) is the first PD-1 inhibitor to demonstrate superior overall survival versus standard of care (docetaxel) in...
Press Releases
Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO...
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will host a teleconference on Monday, June 1, 2015, at 7 p.m. EDT (6 p.m. CDT) to review data...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.